An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia

Bibliography

• Estey E. Aml in older patients: are we making progress? Best Pract Res Clin Haematol 2009;22(4):529-36
   PubMed Web of Science ®Google Scholar
• Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol 2009;37(6):649-58
   PubMed Web of Science ®Google Scholar
• Miraki-Moud F, Anjos-Afonso F, Hodby KA, et al. Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. Proc Natl Acad Sci USA 2013;110(33):13576-81
   PubMed Web of Science ®Google Scholar
• Stone RM, O’Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2004;2004:98-117
   Google Scholar
• Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 2013;88(4):318-27
   PubMed Web of Science ®Google Scholar
• Facts spring 2013. Leukemia and Lymphoma Society; 2013
   Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3(7):730-7
   PubMed Web of Science ®Google Scholar
• Dick JE. Acute myeloid leukemia stem cells. Ann N Y Acad Sci 2005;1044:1-5
   PubMed Web of Science ®Google Scholar
• Jordan CT. The leukemic stem cell. Best Pract Res Clin Haematol 2007;20(1):13-18
   PubMed Web of Science ®Google Scholar
• Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011;29(5):591-9
   PubMed Web of Science ®Google Scholar
• Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012;150(2):264-78
   PubMed Web of Science ®Google Scholar
• Levine RL. Molecular pathogenesis of aml: translating insights to the clinic. Best Pract Res Clin Haematol 2013;26(3):245-8
   PubMed Web of Science ®Google Scholar
• Kroeger H, Jelinek J, Estecio MR, et al. Aberrant cpg island methylation in acute myeloid leukemia is accentuated at relapse. Blood 2008;112(4):1366-73
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Abboud CN, Altman J, et al. Acute myeloid leukemia. J Natl Compr Canc Netw 2012;10(8):984-1021
   PubMed Web of Science ®Google Scholar
• Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012;366(12):1090-8
   PubMed Web of Science ®Google Scholar
• Visconte V, Selleri C, Maciejewski JP, Tiu RV. Molecular pathogenesis of myelodysplastic syndromes. Transl Med UniSa 2014;8:19-30
   PubMedGoogle Scholar
• Kayser S, Dohner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (aml) on outcome in 2853 adult patients with newly diagnosed aml. Blood 2011;117(7):2137-45
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999;17(11):3569-76
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106(5):1090-8
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the european leukemianet. Blood 2010;115(3):453-74
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J, et al. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 2008;113(7 Suppl):1933-52
   PubMed Web of Science ®Google Scholar
• Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011;29(5):487-94
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol 2011;152(5):524-42
   PubMed Web of Science ®Google Scholar
• Estey EH. Adaptive randomization in a treatment study of patients with adverse karyotype acute myeloid leukemia. Curr Oncol Rep 2003;5(5):390
   PubMedGoogle Scholar
• Medeiros BC, Othus M, Estey EH, et al. Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. Br J Haematol 2014;164(2):245-50
   PubMed Web of Science ®Google Scholar
• Estey EH. Older adults: should the paradigm shift from standard therapy? Best Pract Res Clin Haematol 2008;21(1):61-6
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361(13):1235-48
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to low-dose ara-c improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the lrf aml14 and ncri aml16 pick-a-winner comparison. Leukemia 2013;27(1):75-81
   PubMed Web of Science ®Google Scholar
• Al-Ali HK, Jaekel N, Niederwieser D. The role of hypomethylating agents in the treatment of elderly patients with aml. J Geriatr Oncol 2014;5(1):89-105
   PubMed Web of Science ®Google Scholar
• Lubbert M, Bertz H, Ruter B, et al. Non-intensive treatment with low-dose 5-aza-2’-deoxycytidine (dac) prior to allogeneic blood sct of older mds/aml patients. Bone Marrow Transplant 2009;44(9):585-8
   PubMed Web of Science ®Google Scholar
• Lubbert M, Ruter BH, Claus R, et al. A multicenter phase ii trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012;97(3):393-401
   PubMed Web of Science ®Google Scholar
• Malik P, Cashen AF. Decitabine in the treatment of acute myeloid leukemia in elderly patients. Cancer Manage Res 2014;6:53-61
   PubMed Web of Science ®Google Scholar
• Agura E, Cooper B, Holmes H, et al. Report of a phase ii study of clofarabine and cytarabine in de novo and relapsed and refractory aml patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist 2011;16(2):197-206
   PubMed Web of Science ®Google Scholar
• Amadori S, Stasi R, Martelli AM, et al. Temsirolimus, an mtor inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase ii gimema study (aml-1107). Br J Haematol 2012;156(2):205-12
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013;122(8):1384-94
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010;28(14):2389-95
   PubMed Web of Science ®Google Scholar
• Lin TL, Levy MY. Acute myeloid leukemia: focus on novel therapeutic strategies. Clin Med Insights Oncol 2012;6:205-17
   PubMedGoogle Scholar
• Martinez-Cuadron D, Montesinos P, Oriol A, et al. Phase ii trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. Ann Hematol 2014;93(1):43-6
   PubMed Web of Science ®Google Scholar
• Sampat K, Kantarjian H, Borthakur G. Clofarabine: emerging role in leukemias. Expert Opin Investig Drugs 2009;18(10):1559-64
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Gundacker H, Lancet J, et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: southwest oncology group study s0605. Blood 2011;118(3):523-8
   PubMed Web of Science ®Google Scholar
• Corsetti MT, Salvi F, Perticone S, et al. Hematologic improvement and response in elderly aml/raeb patients treated with valproic acid and low-dose ara-c. Leuk Res 2011;35(8):991-7
   PubMed Web of Science ®Google Scholar
• Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013;121(24):4854-60
   PubMed Web of Science ®Google Scholar
• Pleyer L, Stauder R, Burgstaller S, et al. Azacitidine in patients with who-defined aml - results of 155 patients from the austrian azacitidine registry of the agmt-study group. J Hematol Oncol 2013;6:32
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, et al. Cancer, Leukemia Group B: further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group b. J Clin Oncol 2006;24(24):3895-903
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28(4):562-9
   PubMed Web of Science ®Google Scholar
• Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2011;2011:43-50
   PubMedGoogle Scholar
• Lim MY, Jamieson K. Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients. Clin Interv Aging 2014;9:753-62
   PubMed Web of Science ®Google Scholar
• van der Helm LH, Veeger NJ, Kooy M, et al. Azacitidine results in comparable outcome in newly diagnosed aml patients with more or less than 30% bone marrow blasts. Leuk Res 2013;37(8):877-82
   PubMed Web of Science ®Google Scholar
• Shaffer BC, Gillet JP, Patel C, et al. Drug resistance: still a daunting challenge to the successful treatment of aml. Drug Resist Updat 2012;15(1-2):62-9
   PubMed Web of Science ®Google Scholar
• Rathnasabapathy R, Lancet JE. Management of acute myelogenous leukemia in the elderly. Cancer Contr 2003;10(6):469-77
   PubMedGoogle Scholar
• Lichtman SM, Balducci L, Aapro M. Geriatric oncology: a field coming of age. J Clin Oncol 2007;25(14):1821-3
   PubMed Web of Science ®Google Scholar
• Eleni LD, Nicholas ZC, Alexandros S. Challenges in treating older patients with acute myeloid leukemia. J Oncol 2010;2010:943823
   PubMedGoogle Scholar
• Hilmer SN, Shenfield GM, Le Couteur DG. Clinical implications of changes in hepatic drug metabolism in older people. Ther Clin Risk Manag 2005;1(2):151-6
   PubMedGoogle Scholar
• Momparler RL. Optimization of cytarabine (ara-c) therapy for acute myeloid leukemia. Exp Hematol Oncol 2013;2(1):20
   PubMedGoogle Scholar
• Tsai S. Importance of lean body mass in the oncologic patient. Nutr Clin Pract 2012;27(5):593-8
   PubMed Web of Science ®Google Scholar
• Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci 2013;102(9):2941-52
   PubMed Web of Science ®Google Scholar
• Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000;5(3):224-37
   PubMedGoogle Scholar
• Lapinski L, Orzechowska-Juzwenko K, Wiela-Hojenska A, et al. Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia. Pharmacol Rep 2011;63(1):149-56
   PubMed Web of Science ®Google Scholar
• Capizzi RL, Yang JL, Cheng E, et al. Alteration of the pharmacokinetics of high-dose ara-c by its metabolite, high ara-u in patients with acute leukemia. J Clin Oncol 1983;1(12):763-71
   PubMed Web of Science ®Google Scholar
• Sundaram M, Yao SY, Ingram JC, et al. Topology of a human equilibrative, nitrobenzylthioinosine (nbmpr)-sensitive nucleoside transporter (hent1) implicated in the cellular uptake of adenosine and anti-cancer drugs. J Biol Chem 2001;276(48):45270-5
   PubMed Web of Science ®Google Scholar
• Kim KI, Huh IS, Kim IW, et al. Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (aml) patients. Eur J Cancer 2013;49(2):403-10
   PubMed Web of Science ®Google Scholar
• Carrabba MG, Reni M, Foppoli M, et al. Treatment approaches for primary cns lymphomas. Expert Opin Pharmacother 2010;11(8):1263-76
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddemann W, Berdel WE, et al. 6-thioguanine, cytarabine, and daunorubicin (tad) and high-dose cytarabine and mitoxantrone (ham) for induction, tad for consolidation, and either prolonged maintenance by reduced monthly tad or tad-ham-tad and one course of intensive consolidation by sequential ham in adult patients at all ages with de novo acute myeloid leukemia (aml): a randomized trial of the german aml cooperative group. J Clin Oncol 2003;21(24):4496-504
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001;15(6):875-90
   PubMed Web of Science ®Google Scholar
• Horikoshi A, Iriyama N, Hirabayashi Y, et al. Efficacy of oral cytarabine ocfosfate and etoposide in the treatment of elderly patients with higher-risk myelodysplastic syndromes compared to that in elderly acute myeloid leukemia patients. Chemotherapy 2013;59(2):152-8
   PubMed Web of Science ®Google Scholar
• Cai J, Damaraju VL, Groulx N, et al. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res 2008;68(7):2349-57
   PubMed Web of Science ®Google Scholar
• Veuger MJ, Honders MW, Willemze R, Barge RM. Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia. Eur J Haematol 2002;69(3):171-8
   PubMed Web of Science ®Google Scholar
• van den Heuvel-Eibrink MM, Wiemer EA, Kuijpers M, et al. Absence of mutations in the deoxycytidine kinase (dck) gene in patients with relapsed and/or refractory acute myeloid leukemia (aml). Leukemia 2001;15(5):855-6
   PubMed Web of Science ®Google Scholar
• Grant S. Ara-c: cellular and molecular pharmacology. Adv Cancer Res 1998;72:197-233
   PubMed Web of Science ®Google Scholar
• Gati WP, Paterson AR, Larratt LM, et al. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with saenta-fluorescein. Blood 1997;90(1):346-53
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Thomas X, Calvo F, et al. Potential mechanisms of resistance to cytarabine in aml patients. Leuk Res 2002;26(7):621-9
   PubMed Web of Science ®Google Scholar
• Arellano M, Winton E, Pan L, et al. High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years. Cancer 2012;118(2):428-33
   PubMed Web of Science ®Google Scholar
• Luger SM. Treating the elderly patient with acute myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 2010;2010:62-9
   PubMedGoogle Scholar
• Lowenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 2013;121(1):26-8
   PubMed Web of Science ®Google Scholar
• Russell NH. Improving outcomes for elderly patients with aml. Lancet Oncol 2012;13(11):1065-6
   PubMed Web of Science ®Google Scholar
• Crivellari D, Lombardi D, Spazzapan S, et al. New oral drugs in older patients: a review of idarubicin in elderly patients. Crit Rev Oncol Hematol 2004;49(2):153-63
   PubMed Web of Science ®Google Scholar
• Robert J, Rigal-Huguet F, Hurteloup P. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hematol Oncol 1992;10(2):111-16
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Baer MR, Carabasi MH, et al. Nccn practice guidelines for acute myelogenous leukemia. Oncology 2000;14(11A):53-61
   PubMed Web of Science ®Google Scholar
• Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the alfa-9801 study. J Clin Oncol 2010;28(5):808-14
   PubMed Web of Science ®Google Scholar
• Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366(12):1079-89
   PubMed Web of Science ®Google Scholar
• Latagliata R, Breccia M, Fazi P, et al. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the gimema gsi 103 amle randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br J Haematol 2008;143(5):681-9
   PubMed Web of Science ®Google Scholar
• Bains OS, Szeitz A, Lubieniecka JM, et al. A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin. J Pharmacol Exp Ther 2013;347(2):375-87
   PubMed Web of Science ®Google Scholar
• Gewirtz DA, Yanovich S. Metabolism of the anthracycline antibiotic daunorubicin to daunorubicinol and deoxydaunorubicinol aglycone in hepatocytes isolated from the rat and the rabbit. Biochem Pharmacol 1986;35(22):4059-64
   PubMed Web of Science ®Google Scholar
• Bogason A, Masquelier M, Lafolie P, et al. Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia. Drug Metabol Lett 2010;4(4):228-32
   PubMedGoogle Scholar
• Bains OS, Karkling MJ, Lubieniecka JM, et al. Naturally occurring variants of human cbr3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther 2010;332(3):755-63
   PubMed Web of Science ®Google Scholar
• Balendiran GK. Fibrates in the chemical action of daunorubicin. Curr Cancer Drug Targets 2009;9(3):366-9
   PubMed Web of Science ®Google Scholar
• Bains OS, Karkling MJ, Grigliatti TA, et al. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metabol Dispos 2009;37(5):1107-14
   PubMed Web of Science ®Google Scholar
• Leoni F, Ciolli S, Giuliani G, et al. Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. Br J Haematol 1995;90(1):169-74
   PubMed Web of Science ®Google Scholar
• van der Kolk DM, de Vries EG, Muller M, Vellenga E. The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma 2002;43(4):685-701
   PubMed Web of Science ®Google Scholar
• Walter RB, Gooley TA, van der Velden VH, et al. Cd33 expression and p-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007;109(10):4168-70
   PubMed Web of Science ®Google Scholar
• Walter RB, Raden BW, Kamikura DM, et al. Influence of cd33 expression levels and itim-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2005;105(3):1295-302
   PubMed Web of Science ®Google Scholar
• Pollard JA, Alonzo TA, Loken M, et al. Correlation of cd33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood aml. Blood 2012;119(16):3705-11
   PubMed Web of Science ®Google Scholar
• Dowell JA, Korth-Bradley J, Liu H, et al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001;41(11):1206-14
   PubMed Web of Science ®Google Scholar
• Brouwer CA, Gietema JA, van den Berg MP, et al. Long-term cardiac follow-up in survivors of a malignant bone tumour. Ann Oncol 2006;17(10):1586-91
   PubMed Web of Science ®Google Scholar
• Estey E, Plunkett W, Gandhi V, et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 1993;9(4-5):343-50
   PubMed Web of Science ®Google Scholar
• Petti MC, Mandelli F, Avvisati G, et al. High-dose ara-c (hidac) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: a pilot multicentric study by the italian cooperative group gimema. Eur J Haematol 1989;42(1):24-31
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Jeha S, Gandhi V, et al. Clofarabine: past, present, and future. Leuk Lymphoma 2007;48(10):1922-30
   PubMed Web of Science ®Google Scholar
• Ferrara F. Treatment of unfit patients with acute myeloid leukemia: a still open clinical challenge. Clin Lymphoma, Myeloma Leuk 2011;11(1):10-16
   PubMed Web of Science ®Google Scholar
• Rowe JA, Andersen JW, Mazza JJ, et al. A randomized, placebo-controlled phase iii study of granulocyte-macrophage colony stimulating factor in adult patients (.55 to 70 years of age) with acute myelogenous leukemia: a study of the eastern cooperative oncology group (e1490). Blood 1995;86:457-62
   PubMed Web of Science ®Google Scholar
• Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. Aml cooperative study group. N Engl J Med 1995;332(25):1678-83
   PubMed Web of Science ®Google Scholar
• Witz F, Sadoun A, Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe ouest est leucemies aigues myeloblastiques (goelam). Blood 1998;91(8):2722-30
   PubMed Web of Science ®Google Scholar
• Bug G, Koschmieder S, Krauter J, et al. Long-term results of a prospective randomized trial evaluating g-csf priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. Ann Hematol 2014;93(2):193-202
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia group b. N Engl J Med 1994;331(14):896-903
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011;364(11):1027-36
   PubMed Web of Science ®Google Scholar
• Clark WM. Efficacy of citicoline as an acute stroke treatment. Expert Opin Pharmacother 2009;10(5):839-46
   PubMed Web of Science ®Google Scholar
• Chhikara BS, Parang K. Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opin Drug Deliv 2010;7(12):1399-414
   PubMed Web of Science ®Google Scholar
• van der Holt B, Lowenberg B, Burnett AK, et al. The value of the mdr1 reversal agent psc-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (aml), in relation to mdr1 status at diagnosis. Blood 2005;106(8):2646-54
   PubMed Web of Science ®Google Scholar
• Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the united states, 2001-2007. Blood 2012;119(1):34-43
   PubMed Web of Science ®Google Scholar
• Liesveld J. Management of aml: who do we really cure? Leuk Res 2012;36(12):1475-80
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase iii study of the european organization for research and treatment of cancer leukemia group. J Clin Oncol 1989;7(9):1268-74
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (aml) in older patients: the results of the united kingdom medical research council aml11 trial. Blood 2001;98(5):1302-11
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European organization for the research and treatment of cancer and the dutch-belgian hemato-oncology cooperative hovon group. J Clin Oncol 1998;16(3):872-81
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Sekeres MA, Ribrag V, et al. Phase i study assessing the safety and tolerability of barasertib (azd1152) with low-dose cytosine arabinoside in elderly patients with aml. Clin Lymphoma Myeloma Leuk 2013;13(5):559-67
   PubMed Web of Science ®Google Scholar
• Bertoli S, Berard E, Huguet F, et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood 2013;121(14):2618-26
   PubMed Web of Science ®Google Scholar
• Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 2012;97(12):1916-24
   PubMed Web of Science ®Google Scholar
• Nguyen L, Chatelut E, Chevreau C, et al. Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 1998;41(2):125-32
   PubMed Web of Science ®Google Scholar
• Tranchand B, Amsellem C, Chatelut E, et al. A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 1999;43(4):316-22
   PubMed Web of Science ®Google Scholar